Literature DB >> 9121763

Cell scattering of SK-N-MC neuroepithelioma cells in response to Ret and FGF receptor tyrosine kinase activation is correlated with sustained ERK2 activation.

A A van Puijenbroek1, D H van Weering, C E van den Brink, J L Bos, P T van der Saag, S W de Laat, J den Hertog.   

Abstract

The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in kidney and enteric nervous system development. Germline mutations in c-ret are responsible for the dominantly inherited cancer syndromes, multiple endocrine neoplasia types 2A and 2B and familial medullary thyroid carcinoma as well as the developmental disorder Hirschsprung's disease. Using SK-N-MC neuroepithelioma cells stably transfected with an EGFR/Ret chimeric receptor, we have studied cellular consequences and signalling events following activation of exogenous EGFR/Ret and endogenous FGF and PDGF receptor tyrosine kinases in cells of neuroectodermal origin. Here we report that Ret activation led to cell scattering, growth inhibition and loss of anchorage-independent growth. Basic FGF, but not PDGF, evoked similar responses in those cells. Nevertheless, activation of all three receptor tyrosine kinases led to ERK2 activation. Analysis of the kinetics of ERK2 activation and downstream events revealed that Ret and FGF receptor activation led to sustained ERK2 activation and SRE transactivation, while PDGF treatment led to transient ERK2 activation and failed to induce SRE transactivation. Our results suggest that sustained, but not transient ERK2 activation may be involved in cell scattering.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121763     DOI: 10.1038/sj.onc.1200911

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Induction of Id-1 by FGF-2 involves activity of EGR-1 and sensitizes neuroblastoma cells to cell death.

Authors:  Giovanni Passiatore; Antonio Gentilella; Slava Rom; Marco Pacifici; Valeria Bergonzini; Francesca Peruzzi
Journal:  J Cell Physiol       Date:  2011-07       Impact factor: 6.384

2.  Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous Ras.

Authors:  D H van Weering; J de Rooij; B Marte; J Downward; J L Bos; B M Burgering
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

3.  The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho.

Authors:  F N Leeuwen; H E Kain; R A Kammen; F Michiels; O W Kranenburg; J G Collard
Journal:  J Cell Biol       Date:  1997-11-03       Impact factor: 10.539

4.  The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells.

Authors:  Gunnar Schuetz; Marta Rosário; Jan Grimm; Tobias M Boeckers; Eckart D Gundelfinger; Walter Birchmeier
Journal:  J Cell Biol       Date:  2004-11-29       Impact factor: 10.539

5.  The RET-glial cell-derived neurotrophic factor (GDNF) pathway stimulates migration and chemoattraction of epithelial cells.

Authors:  M J Tang; D Worley; M Sanicola; G R Dressler
Journal:  J Cell Biol       Date:  1998-09-07       Impact factor: 10.539

6.  FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines.

Authors:  I El-Hariry; M Pignatelli; N R Lemoine
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

7.  Lack of EGF receptor contributes to drug sensitivity of human germline cells.

Authors:  S-J Park; S Armstrong; C-H Kim; M Yu; K Robertson; M R Kelley; S-H Lee
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

8.  Proteomic Identification of DNA-PK Involvement within the RET Signaling Pathway.

Authors:  Lyle J Burdine; Marie Schluterman Burdine; Linley Moreland; Brad Fogel; Lisa M Orr; Jennifer James; Richard H Turnage; Alan J Tackett
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.